Q&A Project Optimus: What you need to know

Published on: Oct 11, 2022

The study designs and dose-finding strategies that have dominated decades of oncology drug development are becoming obsolete as the FDA’s Project Optimus takes full effect. We rounded up our regulatory experts and asked them to share their perspectives on 28 of the top questions from sponsors.


Open PDF

Return to Insights Center

Related Insights

Blog

PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers

Oct 4, 2024

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Article

Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Nov 10, 2022

Webinar

Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)

Nov 12, 2024

Webinar

Navigating the complexities of AML drug development

Oct 30, 2024

Webinar

Advancing mRNA-based drug development and vaccine manufacturing

Jul 1, 2024

Blog

Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications

Feb 4, 2025

Blog

Population variability: important considerations in vaccine development

Jun 14, 2023

Blog

A hybrid model supports globally diverse site participation for a retrospective cancer study

Jul 24, 2023

Article

The technologies that are reshaping biotherapeutics manufacturing, an EU perspective

Jul 6, 2023

Whitepaper

How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU

Jun 28, 2023

Blog

Be ready for unannounced foreign inspections by US FDA

Sep 5, 2025

Related Insights

Blog

PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers

Oct 4, 2024

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Article

Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Nov 10, 2022

Webinar

Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)

Nov 12, 2024

Webinar

Navigating the complexities of AML drug development

Oct 30, 2024

Webinar

Advancing mRNA-based drug development and vaccine manufacturing

Jul 1, 2024

Show more